Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TERN-101 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| TERN-101 | DRUG | Investigational drug |
| Placebo | OTHER | Matching placebo |
TERN-101 is an investigational small molecule being developed for the treatment of nonalcoholic steatohepatitis (NASH), a liver condition characterized by fat accumulation and inflammation. It is intended for patients with non-cirrhotic NASH. The drug is currently in clinical development and has not been approved by regulatory authorities.
TERN-101 is a small molecule, but its specific molecular target has not been disclosed in available information. The drug is being studied for its effects on NASH, a metabolic liver disease. Clinical trials are evaluating its safety, tolerability, efficacy, and pharmacokinetics in patients with non-cirrhotic NASH.
TERN-101 is being developed by Terns Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol TERN. The company is focused on developing therapies for metabolic diseases, including NASH. TERN-101 is one of its lead investigational candidates.
TERN-101 is in Phase 2 clinical development. It has completed a Phase 2 study, the LIFT Study, which evaluated the drug in patients with non-cirrhotic NASH. The drug remains investigational and has not received FDA approval. Further development may be required before it can be considered for regulatory submission.
TERN-101 has been studied in one clinical trial, the LIFT Study (NCT04328077). This was a Phase 2, uncontrolled trial that enrolled 101 participants with non-cirrhotic NASH. The study assessed safety, tolerability, efficacy, and pharmacokinetics. The trial has been completed, and no active trials are currently listed.
TERN-101 is a distinct investigational drug developed by Terns Pharmaceuticals. No alternative names or other designations have been associated with this compound in available information. It is not known to be identical to any other marketed or investigational medication for NASH or other conditions.